These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 15804371

  • 1. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.
    Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ.
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):427-38. PubMed ID: 15804371
    [Abstract] [Full Text] [Related]

  • 2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M.
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [Abstract] [Full Text] [Related]

  • 4. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.
    Lasser RA, Bossie CA, Gharabawi GM, Kane JM.
    Schizophr Res; 2005 Sep 15; 77(2-3):215-27. PubMed ID: 15908183
    [Abstract] [Full Text] [Related]

  • 5. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F, Schreiner A, Thomas P, Sherif T.
    Clin Drug Investig; 2012 Apr 01; 32(4):267-79. PubMed ID: 22339430
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M.
    Int J Geriatr Psychiatry; 2004 Sep 01; 19(9):898-905. PubMed ID: 15352149
    [Abstract] [Full Text] [Related]

  • 7. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.
    van Os J, Bossie CA, Lasser RA.
    Int Clin Psychopharmacol; 2004 Jul 01; 19(4):229-32. PubMed ID: 15201570
    [Abstract] [Full Text] [Related]

  • 8. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
    Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O.
    J Clin Psychiatry; 2003 Oct 01; 64(10):1250-7. PubMed ID: 14658976
    [Abstract] [Full Text] [Related]

  • 9. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
    Kimura H, Kanahara N, Komatsu N, Ishige M, Muneoka K, Yoshimura M, Yamanaka H, Suzuki T, Komatsu H, Sasaki T, Hashimoto T, Hasegawa T, Shiina A, Ishikawa M, Sekine Y, Shiraishi T, Watanabe H, Shimizu E, Hashimoto K, Iyo M.
    Schizophr Res; 2014 May 01; 155(1-3):52-8. PubMed ID: 24667073
    [Abstract] [Full Text] [Related]

  • 10. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.
    Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER.
    J Psychopharmacol; 2005 Sep 01; 19(5 Suppl):32-8. PubMed ID: 16144784
    [Abstract] [Full Text] [Related]

  • 11. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG, Risperidone Long-Acting Trial Investigators (R-LAI).
    Hum Psychopharmacol; 2009 Oct 01; 24(7):574-83. PubMed ID: 19790173
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
    Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA.
    J Affect Disord; 2004 Dec 01; 83(2-3):263-75. PubMed ID: 15555724
    [Abstract] [Full Text] [Related]

  • 13. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM, Bossie CA, Zhu Y, Mao L, Lasser RA.
    Schizophr Res; 2005 Sep 15; 77(2-3):129-39. PubMed ID: 15913962
    [Abstract] [Full Text] [Related]

  • 14. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
    Lasser RA, Bossie CA, Zhu Y, Locklear JC, Kane JM.
    Ann Clin Psychiatry; 2007 Sep 15; 19(2):65-71. PubMed ID: 17612845
    [Abstract] [Full Text] [Related]

  • 15. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.
    Clin Schizophr Relat Psychoses; 2014 Jul 15; 8(2):101-9, 109A. PubMed ID: 23446197
    [Abstract] [Full Text] [Related]

  • 16. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.
    Encephale; 2013 May 15; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [Abstract] [Full Text] [Related]

  • 17. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C, Dusouchet T, Bret P, Queuille E, Biscay ML, Caron J, Bret MC.
    Encephale; 2007 Dec 15; 33(6):973-81. PubMed ID: 18789790
    [Abstract] [Full Text] [Related]

  • 18. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K.
    Hum Psychopharmacol; 2010 Jan 15; 25(1):37-46. PubMed ID: 20041474
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
    Schmauss M, Sacchetti E, Kahn JP, Medori R.
    Int Clin Psychopharmacol; 2007 Mar 15; 22(2):85-92. PubMed ID: 17293708
    [Abstract] [Full Text] [Related]

  • 20. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.
    Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, Rodriguez S, Gharabawi GM.
    J Clin Psychiatry; 2006 Aug 15; 67(8):1194-203. PubMed ID: 16965196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.